Annexon Rg
Clinical‑stage biopharma Annexon focuses on anti‑inflammatory therapies, with lead antibody ANX005 in Phase 3 for Guillain‑Barré and additional candidates in Phase II/III trials for Huntington’s, ALS, geographic atrophy, and autoimmune diseases.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 99
- HQ: Brisbane
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.